Ga733/EpCAM as a target for passive and active specific immunotherapy in patients with colorectal carcinoma

Annals of the New York Academy of Sciences

Volumn 910, Issue , 2000, Pages 254-262

  Mellstedt, Håkan ^a,b   Fagerberg, J ^a   Frodin J E ^a   Hjelm Skog, A L ^a   Liljefors, M ^a   Markovic, K ^a   Mosolits, S ^a   Ragnhammar, P ^a  

^a Cancer Centre Karolinska   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CANCER ANTIBODY; CANCER VACCINE; CELL ADHESION MOLECULE; FLUOROURACIL; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MONOCLONAL ANTIBODY; TUMOR ANTIGEN;

ANIMAL EXPERIMENT; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CLINICAL TRIAL; COLORECTAL CARCINOMA; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; FEVER; HUMAN; IMMEDIATE TYPE HYPERSENSITIVITY; MOUSE; NONHUMAN; SIDE EFFECT; TUMOR IMMUNITY; VACCINATION;

ANIMALIA;

EID: 0033941961     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2000.tb06713.x     Document Type: Conference Paper

References (12)

1. 1. SHETYE, J., B. CHRISTENSSON, C. RUBIO, M. RODENSJö, P. BIBERFELD & H. MELLSTEDT. 1989. The tumor-associated antigens BR55-2, GA733-3 and GICA 19-9 in normal and corresponding neoplastic human tissues, especially gastrointestinal tissues. Anti-cancer Res. 9: 395-404.
2. 2. DIGIORGIO, A., C. BOTTI, A. TOCCI, P. MINGAZZINE & M. FLAMMIAN. 1992. The influence of tumor lymphocytic infiltration in long-term survival of surgically treated colorectal carcinoma patients. Int. Surg. 77: 256-260.
3. 3. FAGERBERG, J., P. RAGNHAMMAR, M. LILJEFORS, A-L. HJELM, H. MELLSTEDT & J-E. FRÖDIN. 1996. Humoral anti-idiotypic and anti-anti-idiotypic immune response in cancer patients treated with monoclonal antibody 17-1A. Cancer Immunol. Immunother. 42: 81-87.
4. 4. MOSOLITS, S., U. HARMENBERG, U. RÜDEN, L. ÖHMAN, B. NILSSON, B. WAHREN, J. FAGERBERG & H. MELLSTEDT. 1999. Autoantibodies against the tumor-associated antigen GA733-2 in patients with colorectal carcinoma. Cancer Immunol. Immunother. 47: 315-320.
5. 5. MELLSTEDT, H., J. FAGERBERG, J-E. FRÖDIN, L. HENRIKSSON, A-L. HJELM-SKOG, M. LILJEFORS, P. RAGNHAMMAR, J. SHETYE & A. ÖSTERBORG. 1999. Augmentation of the immune response with granulocyte-macrophage colony-stimulating factor and other hematopoietic growth facors. Curr. Opin. Hematol. 6: 169-175.
6. 6. MASUCCI, G., P. RAGNHAMMAR, P. WERSÄLL & H. MELLSTEDT. 1990. Granulocyte-monocyte colony-stimulating factor augments the interleukin-2 induced cytotoxic activity of human lymphocytes in the absence and presence of mouse or chimeric monoclonal antibodies (MAb17-1A). Cancer Immunol. Immunother. 31: 231-235.
7. 7. MASUCCI, G. & H. MELLSTEDT. 1991. Combinations of IL-2, GM-CSF, IL-4, IFN-α and TNF-α increase the antibody-dependent cellular cytotoxicity (ADCC) of blood mononuclear cells in presence of either mouse or chimeric MAb17-1A. A preclinical evaluation. Cancer J. 4: 168-173.
8. 8. RAGNHAMMAR, P., J-E. FRÖDIN, A-L. HJELM, J. FAGERBERG, P. WERSÄLL, C. LINDEMALM, B. NILSSON, K. FOX, I. MAGNUSSON, S. EWERTH, K. THOR, E. SECHER & H. MELLSTEDT. 1995. Different dose regimens of the mouse monoclonal antibody 17-1A for therapy of patients with metastatic colorectal carcinoma. Int. J. Oncol. 7: 1049-1056.
9. 9. HJELM-SKOG, A-L., P. RAGNHAMMAR, J. FAGERBERG, J-E. FRÖDIN, M. GOLDINGER, H. KOLDESTAM, M. LILJEFORS, B. NILSSON, J. SHETYE, P. WERSÄLL & H. MELLSTEDT. 1999. Clinical effects of monoclonal antibody 17-1A combined with granulocyte/ macrophage-colony-stimulating factor and interleukin-2 for treatment of patients with advanced colorectal carcinoma. Cancer Immunol. Immunother. 48: 463-470.
10. 10. RIETHMÜLLER, G., E. HOLZ, G. SCHLIMOK, W. SCHMIEGEL, R. RAAB, K. HOFFKEN, R. GRUBER, H. FUNKE, H. PICHLMAIER, H. HIRCHE, P. BUGGISCH, J. WITTE & R. PICHLMAYR. 1998. Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial. J. Clin. Oncol. 16: 1788-1794.
11. 11. MELLSTEDT, H., J. FAGERBERG & A. ÖSTERBORG. 1999. Local low-dose of soluble GM-CSF significantly augments an immune response against tumour antigens in man. Eur. J. Cancer 35: 29-32.
12. 12. SAMANCI, A., Q. YI, J. FAGERBERG, K. STRIGȦRD, G. SMITH, U. RÜDEN, B. WAHREN & H. MELLSTEDT. 1998. Pharmacological administration of granulocyte/macrophage-colony-stimulating factor is of significant importance for the induction of a strong humoral and cellular response in patients immunized with recombinant carcinoembryonic antigen. Cancer Immunol. Immunother 47: 131-142.